{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=BI+10773+high+dose",
    "query": {
      "intervention": "BI 10773 high dose"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 23,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=BI+10773+high+dose&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-01T20:49:40.019Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01649297",
      "title": "A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "empagliflozin (low dose qd)",
          "type": "DRUG"
        },
        {
          "name": "Empagliflozin (high dose qd)",
          "type": "DRUG"
        },
        {
          "name": "empagliflozin (high dose bid)",
          "type": "DRUG"
        },
        {
          "name": "empagliflozin (low dose bid)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 983,
      "start_date": "2012-10",
      "completion_date": "2013-12",
      "has_results": true,
      "last_update_posted_date": "2015-07-23",
      "last_synced_at": "2026-09-01T20:49:40.019Z",
      "location_count": 39,
      "location_summary": "Florence, Alabama • Jonesboro, Arkansas • Lomita, California + 34 more",
      "locations": [
        {
          "city": "Florence",
          "state": "Alabama"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Lomita",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Rancho Cucamonga",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01649297"
    },
    {
      "nct_id": "NCT01719003",
      "title": "Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2",
        "Hyperglycemia"
      ],
      "interventions": [
        {
          "name": "Metformin 500 mg bid",
          "type": "DRUG"
        },
        {
          "name": "Metformin 1000 mg bid",
          "type": "DRUG"
        },
        {
          "name": "Empagliflozin low dose qd",
          "type": "DRUG"
        },
        {
          "name": "Empagliflozin high dose qd",
          "type": "DRUG"
        },
        {
          "name": "Empagliflozin low dose bid",
          "type": "DRUG"
        },
        {
          "name": "Empagliflozin high dose bid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1413,
      "start_date": "2012-10",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2016-02-19",
      "last_synced_at": "2026-09-01T20:49:40.019Z",
      "location_count": 41,
      "location_summary": "Birmingham, Alabama • Manley Hot Springs, Alaska • Glendale, Arizona + 33 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Manley Hot Springs",
          "state": "Alaska"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Searcy",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01719003"
    },
    {
      "nct_id": "NCT01422876",
      "title": "Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "high dose FDC",
          "type": "DRUG"
        },
        {
          "name": "BI 10773 high dose",
          "type": "DRUG"
        },
        {
          "name": "high dose FDC placebo",
          "type": "DRUG"
        },
        {
          "name": "low dose FDC placebo",
          "type": "DRUG"
        },
        {
          "name": "high dose BI 10773 placebo",
          "type": "DRUG"
        },
        {
          "name": "low dose FDC",
          "type": "DRUG"
        },
        {
          "name": "BI 10773 low dose",
          "type": "DRUG"
        },
        {
          "name": "linagliptin",
          "type": "DRUG"
        },
        {
          "name": "linagliptin placebo",
          "type": "DRUG"
        },
        {
          "name": "BI 10773 low dose placebo",
          "type": "DRUG"
        },
        {
          "name": "low dose BI 10773 placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1405,
      "start_date": "2011-08",
      "completion_date": "2013-09",
      "has_results": true,
      "last_update_posted_date": "2015-04-02",
      "last_synced_at": "2026-09-01T20:49:40.019Z",
      "location_count": 112,
      "location_summary": "Birmingham, Alabama • Foley, Alabama • Mobile, Alabama + 90 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Foley",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Pell City",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01422876"
    },
    {
      "nct_id": "NCT00881530",
      "title": "Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "BI 10773",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        },
        {
          "name": "Sitagliptin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 660,
      "start_date": "2009-03",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2014-06-16",
      "last_synced_at": "2026-09-01T20:49:40.019Z",
      "location_count": 12,
      "location_summary": "Mission Viejo, California • Spring Valley, California • Walnut Creek, California + 9 more",
      "locations": [
        {
          "city": "Mission Viejo",
          "state": "California"
        },
        {
          "city": "Spring Valley",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Clearwarter",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00881530"
    },
    {
      "nct_id": "NCT01159600",
      "title": "Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Placebo identical to BI 10773 high dose",
          "type": "DRUG"
        },
        {
          "name": "Placebo identical to BI 10773 low dose",
          "type": "DRUG"
        },
        {
          "name": "BI 10773",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1504,
      "start_date": "2010-07",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2014-06-17",
      "last_synced_at": "2026-09-01T20:49:40.019Z",
      "location_count": 25,
      "location_summary": "Birmingham, Alabama • Tempe, Arizona • Huntington Park, California + 21 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Huntington Park",
          "state": "California"
        },
        {
          "city": "Huntington Park",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01159600"
    },
    {
      "nct_id": "NCT03152552",
      "title": "A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus and Heart Failure"
      ],
      "interventions": [
        {
          "name": "LIK066",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Empagliflozin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 125,
      "start_date": "2017-07-25",
      "completion_date": "2018-06-06",
      "has_results": true,
      "last_update_posted_date": "2019-08-28",
      "last_synced_at": "2026-09-01T20:49:40.019Z",
      "location_count": 21,
      "location_summary": "Huntsville, Alabama • Carmichael, California • Concord, California + 18 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Carmichael",
          "state": "California"
        },
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03152552"
    },
    {
      "nct_id": "NCT01177813",
      "title": "Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Placebo identical to BI10773 high dose",
          "type": "DRUG"
        },
        {
          "name": "BI 10773",
          "type": "DRUG"
        },
        {
          "name": "BI 10773 open label",
          "type": "DRUG"
        },
        {
          "name": "Placebo identical to BI10773 low dose",
          "type": "DRUG"
        },
        {
          "name": "Placebo identical to Sitagliptin 100mg",
          "type": "DRUG"
        },
        {
          "name": "BI10773",
          "type": "DRUG"
        },
        {
          "name": "Sitagliptin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 986,
      "start_date": "2010-07",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2014-06-16",
      "last_synced_at": "2026-09-01T20:49:40.019Z",
      "location_count": 27,
      "location_summary": "Mesa, Arizona • Phoenix, Arizona • Hot Springs, Arkansas + 23 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Chino",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01177813"
    },
    {
      "nct_id": "NCT02182830",
      "title": "24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2",
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "Empagliflozin low dose",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "Empagliflozin high dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 166,
      "start_date": "2014-07-25",
      "completion_date": "2017-05-18",
      "has_results": true,
      "last_update_posted_date": "2018-07-31",
      "last_synced_at": "2026-09-01T20:49:40.019Z",
      "location_count": 92,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 62 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02182830"
    },
    {
      "nct_id": "NCT01370005",
      "title": "12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2",
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "BI 10773",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 825,
      "start_date": "2011-06",
      "completion_date": "2012-07",
      "has_results": true,
      "last_update_posted_date": "2016-02-22",
      "last_synced_at": "2026-09-01T20:49:40.019Z",
      "location_count": 35,
      "location_summary": "Huntsville, Alabama • Phoenix, Arizona • Lincoln, California + 29 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Lincoln",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01370005"
    },
    {
      "nct_id": "NCT01011868",
      "title": "Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "BI 10773 placebo",
          "type": "DRUG"
        },
        {
          "name": "BI 10773 low dose",
          "type": "DRUG"
        },
        {
          "name": "BI 10773 high dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 494,
      "start_date": "2009-11",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2014-09-30",
      "last_synced_at": "2026-09-01T20:49:40.019Z",
      "location_count": 56,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 50 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Gatos",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01011868"
    }
  ]
}